Interspecies scaling of excretory amounts using allometry – retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion

References

• Acred P. (1983). Therapeutic and kinetic properties of ceftazidime in animals. Infection 11:S44–8
   Google Scholar
• Assandri A, Ratti B, Cristina T. (1984). Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J Antibiot (Tokyo) 37:1066–75
   PubMed Web of Science ®Google Scholar
• Benjamin B, Sahu M, Bhatnagar U, et al. (2012). The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds? Arzneimittelforschung 62:194–201
   PubMed Web of Science ®Google Scholar
• Bhamidipati RK, Dravid PV, Mullangi R, Srinivas NR. (2004). Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica 34:571–9
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–27
   PubMedGoogle Scholar
• Bowers GD, Culp A, Reese MJ, et al. (2015). Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica [Epub ahead of print]. doi: 10.3109/00498254.2015.1060372
   Web of Science ®Google Scholar
• Castellino S, Moss L, Wagner D, et al. (2013). Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother 57:3536–46
   PubMed Web of Science ®Google Scholar
• Cirillo I, Mannens G, Janssen C, et al. (2008). Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother 52:3478–83
   PubMed Web of Science ®Google Scholar
• Dalvie DK, Khosla N, Vincent J. (1997). Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos 25:423–7
   PubMed Web of Science ®Google Scholar
• Emary WB, Toren PC, Mathews B, Huh K. (1998). Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. Drug Metab Dispos 26:725–31
   PubMed Web of Science ®Google Scholar
• Feng B, Varma MV, Costales C, et al. (2014). In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery. Expert Opin Drug Discov 9:873–90
   PubMed Web of Science ®Google Scholar
• Goteti K, Garner CE, Mahmood I. (2010). Prediction of human drug clearance from two species: a comparison of several allometric methods. J Pharm Sci 99:1601–13
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2012). Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. J Pharm Sci 101:2645–52
   PubMed Web of Science ®Google Scholar
• Hori T, Nakano M, Kimura Y, Murakami K. (2006). Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 20:91–6
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33
   PubMed Web of Science ®Google Scholar
• Izawa A, Yoshitake A, Komatsu T. (1980). Absorption and excretion of miloxacin in mice, rats, and dogs. Antimicrob Agents Chemother 18:41–4
   PubMed Web of Science ®Google Scholar
• Kita Y, Fugono T, Imada A. (1986). Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 29:127–34
   PubMed Web of Science ®Google Scholar
• Kita Y, Yamazaki T, Imada A. (1992). Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals. Antimicrob Agents Chemother 36:2481–6
   PubMed Web of Science ®Google Scholar
• Li R, Li R, Barton HA, Varma MV. (2014). Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved. Clin Pharmacokinet 53:659–78
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2012). Interspecies scaling of biliary excreted drugs: prediction of human clearance and volume of distribution. Drug Metabol Drug Interact 27:157–64
   PubMedGoogle Scholar
• Mahmood I. (2010). Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor. Clin Pharmacokinet 49:479–92
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2002). Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabol Drug Interact 19:49–64
   PubMedGoogle Scholar
• Mahmood I. (2014). Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling. Haemophilia 20:32–8
   PubMed Web of Science ®Google Scholar
• McNulty CA, Garden GM, Ashby J, Wise R. (1985). Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam. Antimicrob Agents Chemother 28:425–7
   PubMed Web of Science ®Google Scholar
• Mihindu JC, Scheld WM, Bolton ND, et al. (1983). Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother 24:252–61
   PubMed Web of Science ®Google Scholar
• Montay G, Goueffon Y, Roquet F. (1984). Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother 25:463–72
   PubMed Web of Science ®Google Scholar
• Moss L, Wagner D, Kanaoka E, et al. (2015). The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. Xenobiotica 45:60–70
   PubMed Web of Science ®Google Scholar
• Mullangi R, Ahlawat P, Trivedi RK, Srinivas NR. (2009). Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor. Eur J Drug Metab Pharmacokinet 34:57–63
   PubMed Web of Science ®Google Scholar
• Nagilla R, Ward KW. (2004). A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 93:2522–34
   PubMed Web of Science ®Google Scholar
• Norrby SR, Rogers JD, Ferber F, et al. (1984). Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother 26:707–14
   PubMed Web of Science ®Google Scholar
• Obach RS, Nedderman AN, Smith DA. (2012). Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica 42:46–56
   PubMed Web of Science ®Google Scholar
• Paulfeuerborn W, Müller HJ, Borner K, et al. (1993). Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob Agents Chemother 37:1835–41
   PubMed Web of Science ®Google Scholar
• Pavankumar VV, Vinu CA, Mullangi R, Srinivas NR. (2007). Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. Eur J Drug Metab Pharmacokinet 32:29–37
   PubMed Web of Science ®Google Scholar
• Reith K, Keung A, Toren PC, et al. (1998). Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos 26:732–8
   PubMed Web of Science ®Google Scholar
• Sayama H, Komura H, Kogayu M. (2013). Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans-usefulness of exponent on prospective evaluation of predictability. Drug Metab Dispos 41:498–507
   PubMed Web of Science ®Google Scholar
• Sjogren E, Westergren J, Grant I, et al. (2013). In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci 49:679–98
   PubMed Web of Science ®Google Scholar
• Slatter JG, Adams LA, Bush EC, et al. (2002). Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907–24
   PubMed Web of Science ®Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL, et al. (2001). Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 29:1136–45
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2010). Allometry as a tool in drug development. In: Srinivas NR, ed. Drug development perspectives – considerations, challenges and strategies. New York: HNB Publishers, 47–106
   Google Scholar
• Srinivas NR. (2015a). Limited sampling strategy for the prediction of area under the curve (AUC) of statins: reliability of a single time point for AUC prediction for pravastatin and simvastatin. Drug Res(Stuttg); May 26. [Epub ahead of print]
   Web of Science ®Google Scholar
• Srinivas NR. (2015b). Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. Biopharm Drug Dispos. [Epub ahead of print]. doi: 10.1002/bdd.1967
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2015c). Differences in the prediction of area under the curve for a protease inhibitor using trough versus peak concentration: Feasibility assessment using published pharmacokinetic data for indinavir. Amer J Ther. [Epub ahead of print]. doi: 10.1097/MJT.0000000000000294
   Google Scholar
• Srinivas NR. (2015d). Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. Drug Dev Ind Pharm. [Epub ahead of print]. doi: 10.3109/03639045.2015.1096278
   PubMed Web of Science ®Google Scholar
• Teng R, Girard D, Gootz TD, et al. (1996). Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Antimicrob Agents Chemother 40:561–6
   PubMed Web of Science ®Google Scholar
• White RE, Evans DC, Hop CE, et al. (2013). Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary. Xenobiotica 43:219–25
   PubMed Web of Science ®Google Scholar
• Yoshitake A, Kawahara K, Shono F, et al. (1980). Determination of miloxacin and metabolites in human serum and urine by high-pressure liquid chromatography. Antimicrob Agents Chemother 18:45–9
   PubMed Web of Science ®Google Scholar
• Zhang T, Heimbach T, Lin W, et al. (2015). Prospective predictions of human pharmacokinetics for eighteen compounds. J Pharm Sci 104:2795–806
   PubMed Web of Science ®Google Scholar